Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer

Mh, Lü; Tang, Bo; Zeng, Shuo; Cj, Hu; Xie, Ruiqin; Wu, Yan-Guang; Sm, Wang; Ft, He; Sm, Yang

doi:10.1038/onc.2015.413

Cited by 157 publications

(87 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HOTAIR has also been identified as a cell proliferation regulator through binding to EZH2 in glioma cells [53]. Moreover, lncRNA BC032469 can directly bind to miR-1207-5p as a ceRNA that may decrease the expression of telomerase reverse transcriptase in gastric cancer, and UCA1 can sponge miR-485-5ps and antagonize its repression of matrix metallopeptidase 14 in epithelial ovarian cancer cells [54, 55]. Notably, emerging evidence has shown that lncRNAs are also actively involved in cancer cell drug resistance.…”

Section: Long Non-coding Rna In Cancer Cell Drug Resistancementioning

confidence: 99%

Long non-coding RNAs in anti-cancer drug resistance

et al. 2016

View full text Add to dashboard Cite

Chemotherapy is one of the basic treatments for cancers; however, drug resistance is mainly responsible for the failure of clinical treatment. The mechanism of drug resistance is complicated because of interaction among various factors including drug efflux, DNA damage repair, apoptosis and targets mutation. Long non-coding RNAs (lncRNAs) have been a focus of research in the field of bioscience, and the latest studies have revealed that lncRNAs play essential roles in drug resistance in breast cancer, gastric cancer and lung cancer, et al. Dysregulation of multiple targets and pathways by lncRNAs results in the occurrence of chemoresistance. In this review, we will discuss the mechanisms underlying lncRNA-mediated resistance to chemotherapy and the therapeutic potential of lncRNAs in future cancer treatment.

show abstract

Section: Long Non-coding Rna In Cancer Cell Drug Resistancementioning

confidence: 99%

Long non-coding RNAs in anti-cancer drug resistance

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Some studies showed that MEG3 inhibits the tumorigenesis by sponging multiple miRNAs, such as miR-26a in TSCC [11], miR-181a in gastric cancer [36] and miR-21 in cervical cancer [37]. We found that miR-494 was identified to have the potential to bind with MEG3 and exhibit the negative correlation with MEG3 expression in proliferating phase HAs or xenograft tumor tissues.…”

Section: Discussionmentioning

confidence: 71%

lncRNA MEG3 Suppresses the Tumorigenesis of Hemangioma by Sponging miR-494 and Regulating PTEN/ PI3K/AKT Pathway

Dai

Wan

Qiu

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Dysregulation of long noncoding RNAs (lncRNAs) is associated with the proliferation and metastasis in a variety of cancers, of which lncRNA maternally expressed gene 3 (MEG3) has been indicated as a tumor suppressor in multiple malignancies. However, the underlying mechanisms by which MEG3 contributes to human hemangiomas (HAs) remain undetermined. Methods: qRT-PCR analysis was performed to examine the expression levels of MEG3 and VEGF in proliferating or involuting phase HAs. MTT, colony formation assay, flow cytometry analysis and a subcutaneous xenograft tumor model were conducted to assess the effects of MEG3 on the HAs tumorigenesis. The interaction between MEG3 and miRNAs or their downstream pathways was evidenced by bioinformatic analysis, luciferase report assays, RNA immunoprecipitation (RIP) assay. and Western blot analysis. Results: The expression of MEG3 was substantially decreased and had a negative correlation with VEGF expression in proliferating phase HAs, as compared with the involuting phase HAs and normal skin tissues. Ectopic expression of MEG3 suppressed cell proliferation, colony formation and induced cycle arrest in vitro and in vivo, followed by the downregulation of VEGF and cyclinD1, but knockdown of MEG3 reversed these effects. Furthermore, MEG3 was verified to act as a sponge of miR-494 in HAs cells, and miR-494 counteracted MEG3-caused anti-proliferative effects by regulating PTEN/PI3K/AKT pathway, and exhibited the negative correlation with MEG3 and PTEN expression in proliferating phase HAs. Conclusion: Our findings suggested that lncRNA MEG3 inhibited HAs tumorigenesis by sponging miR-494 and regulating PTEN/PI3K/AKT pathway.

show abstract

“…Yang et al (13) revealed that the expression levels of C21 or F96 were associated with gross appearance, lymphatic metastasis and distal metastasis. Lü et al (14) reported lncRNA BC032469 was able to upregulate human telomerase reverse transcriptase (hTERT) expression by sponging microRNA (miR)-1207-5p and promoting proliferation in gastric cancer. Li et al (15) thought TM4SF5-CTD-2354A18.1 miR-4697-3P may play a key role in the pathogenesis of gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

A meta-analysis: The diagnostic values of long non-coding RNA as a biomarker for gastric cancer

Zhao

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have been identified as novel biomarkers for the diagnosis, staging and prognosis for gastric cancer. However, various studies have reported a series of significances based on different diagnostic values. Therefore, the current study performed a systematic review and meta-analysis to evaluate the diagnostic accuracy of lncRNAs for gastric cancer, and to discuss lncRNA types and sources of heterogeneity. The Cochrane Central Register of Controlled Trials, MEDLINE, PubMed, EMBASE, the Chinese Biomedical Literature Database, the China Academic Journals Full-text Database and the Chinese Scientific Journals Database were systematically searched for potential studies. Studies were included if they were associated with lncRNAs, gastric cancer and reported diagnostic outcomes. Analysis of diagnostic values was used to summarize the overall test performance of lncRNAs. Ten studies were included in this meta-analysis. The ranges of the diagnostic value of lncRNAs for gastric cancer were as follows: Sensitivity was 0.45–0.83, and pooled sensitivity was 0.63; specificity was 0.60–0.93, and pooled specificity was 0.75; positive likelihood ratio was 1.80–6.92, and pooled positive likelihood ratio was 2.51; negative likelihood ratio was 0.23–0.67, and pooled negative likelihood ratio was 0.50; diagnostic odds ratio was 3.33–13.75, and pooled diagnostic odds ratio was 5.47. An overall area under the curve value of the summary receiver operating characteristic curve was 0.7550. LncRNAs did not have a high accuracy for identifying gastric cancer at present, but may be a useful screening tool for diagnosing gastric cancer due to their correlation with gastric cancer biological features. LncRNAs are potential biomarkers for gastric cancer if the screening strategy is altered, or they are combined with other biomarkers to diagnose gastric cancer.

show abstract

Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer

Cited by 157 publications

References 38 publications

Long non-coding RNAs in anti-cancer drug resistance

Long non-coding RNAs in anti-cancer drug resistance

lncRNA MEG3 Suppresses the Tumorigenesis of Hemangioma by Sponging miR-494 and Regulating PTEN/ PI3K/AKT Pathway

A meta-analysis: The diagnostic values of long non-coding RNA as a biomarker for gastric cancer

Contact Info

Product

Resources

About